TNF Inhibitors Tied to Lower Risk for Serious, Fatal Covid-19 Outcomes
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Medexus Pharmaceuticals Inc shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021
Medexus Pharmaceuticals IncMarch 1, 2021 GMT
TORONTO, CHICAGO and MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced its financial and operating results for the three and nine months ended December 31, 2020. All dollar amounts below are in Canadian dollars unless specified otherwise.
Third Quarter Fiscal 2021 Financial Highlights: The Company achieved record revenue of $31.5 million for the three-month period ended December 31, 2020, versus $16.2 million for the same period last year. As previously reported, the revenue for the period included approximately $3 million in IXINITY® revenues, which were originally expected to be realized in September 2020, but were instead realized in